Literature DB >> 7493983

Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway.

S Mori1, K Tanaka, S Omura, Y Saito.   

Abstract

The platelet-derived growth factor beta-receptor undergoes polyubiquitination as a consequence of ligand binding. We have previously reported that ligand-induced ubiquitination of the receptor plays a negative regulatory role in its mitogenic signaling possibly by promoting the efficient degradation of the ligand-activated receptor (Mori, S., Heldin, C.-H., and Claesson-Welsh, L. (1993) J. Biol. Chem. 268, 577-583). In the present study, we have examined effects of different kinds of cell-penetrating proteasome inhibitors, including substrate-related peptidyl aldehydes, Cbz-Ile-Glu(O-t-Bu)-Ala-leucinal (where Bu is butyl and Cbz is benzyloxycarbonyl) (PSI) and Cbz-Leu-Leu-norvalinal (MG115), and a Streptomyces metabolite lactacystin, on degradation of the receptor in intact cells with the aim of evaluating the role of the receptor ubiquitination in the proteasome-dependent proteolytic process. These proteasome inhibitors were found to considerably inhibit ligand-stimulated degradation of the wild-type beta-receptor; however, their inhibitory effect was not observed when the cells expressing the ubiquitination-deficient mutant beta-receptor were analyzed. These data suggest that the degradation process of the ligand-stimulated beta-receptor involves the ubiquitin-proteasome proteolytic pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493983     DOI: 10.1074/jbc.270.49.29447

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization.

Authors:  M Martinez-Moczygemba; D P Huston
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins.

Authors:  P van Kerkhof; C M Alves dos Santos; M Sachse; J Klumperman; G Bu; G J Strous
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

3.  Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments.

Authors:  A Rocca; C Lamaze; A Subtil; A Dautry-Varsat
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 4.  Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.

Authors:  Mainak Guharoy; Pallab Bhowmick; Peter Tompa
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

5.  Insulin inhibits platelet-derived growth factor-induced cell proliferation.

Authors:  P Cirri; M L Taddei; P Chiarugi; F Buricchi; A Caselli; P Paoli; E Giannoni; G Camici; G Manao; G Raugei; G Ramponi
Journal:  Mol Biol Cell       Date:  2004-11-03       Impact factor: 4.138

6.  Ubiquitin lys63 is involved in ubiquitination of a yeast plasma membrane protein.

Authors:  J M Galan; R Haguenauer-Tsapis
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

Review 7.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

8.  Ongoing DNA synthesis in the rat cerebral cortex is regulated by a proteolytic pathway independent of the proteasome and calpains.

Authors:  J Sebastián Yakisich; Ake Sidén; Mabel Cruz
Journal:  Invest New Drugs       Date:  2009-03-17       Impact factor: 3.850

Review 9.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

10.  Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway.

Authors:  Shi-Bin Cheng; Jeffrey A Quinn; Carl T Graeber; Edward J Filardo
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.